Abstract
Alzheimers disease (AD) is difficult to diagnose in its early stages, and even if detected early, there is no preventative treatment. Imaging modalities such as MRI, PET, and SPECT have the potential to contribute to both the diagnosis of Alzheimers disease, as well as assist in the search for more effective treatments. A number of AD-related biomarkers have been proposed and evaluated. The use of PET imaging to detect alterations in regional brain metabolism using [18F]FDG has enabled more sensitive and accurate early diagnosis of AD, especially in conjunction with traditional medical evaluation. Additionally, magnetic resonance imaging and spectroscopy provide a wide range of biomarkers that have been shown to correlate with the progression of AD. Some of these markers have been pursued in clinical trials. Progress has been made toward the evaluation of other more AD-specific biomarkers. However, many questions remain concerning the validity and sensitivity of these imaging biomarkers to aid in the assessment of potential new treatments, especially those related to increased levels of amyloid peptides in the brain.
Keywords: Alzheimer's, imaging, biomarker, PET, SPECT, MRI, atrophy, amyloid
Current Topics in Medicinal Chemistry
Title: The Role of MRI and PET/SPECT in Alzheimers Disease
Volume: 6 Issue: 6
Author(s): Alexandre Coimbra, Donald S. Williams and Eric D. Hostetler
Affiliation:
Keywords: Alzheimer's, imaging, biomarker, PET, SPECT, MRI, atrophy, amyloid
Abstract: Alzheimers disease (AD) is difficult to diagnose in its early stages, and even if detected early, there is no preventative treatment. Imaging modalities such as MRI, PET, and SPECT have the potential to contribute to both the diagnosis of Alzheimers disease, as well as assist in the search for more effective treatments. A number of AD-related biomarkers have been proposed and evaluated. The use of PET imaging to detect alterations in regional brain metabolism using [18F]FDG has enabled more sensitive and accurate early diagnosis of AD, especially in conjunction with traditional medical evaluation. Additionally, magnetic resonance imaging and spectroscopy provide a wide range of biomarkers that have been shown to correlate with the progression of AD. Some of these markers have been pursued in clinical trials. Progress has been made toward the evaluation of other more AD-specific biomarkers. However, many questions remain concerning the validity and sensitivity of these imaging biomarkers to aid in the assessment of potential new treatments, especially those related to increased levels of amyloid peptides in the brain.
Export Options
About this article
Cite this article as:
Coimbra Alexandre, Williams S. Donald and Hostetler D. Eric, The Role of MRI and PET/SPECT in Alzheimers Disease, Current Topics in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/156802606776743075
DOI https://dx.doi.org/10.2174/156802606776743075 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Assessment and Relevance of Carotid Intima-Media Thickness (C-IMT) in Primary and Secondary Cardiovascular Prevention
Current Pharmaceutical Design Apolipoprotein E Gene Variants of Alzheimer's Disease and Vascular Dementia Patients in a Community Population of Nanking
Medicinal Chemistry Errors in ADAS-Cog Administration and Scoring May Undermine Clinical Trials Results
Current Alzheimer Research TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology Impact of HLA Haplotype on the Response to Antipsychotic Treatment of Schizophrenia
Current Pharmacogenomics Possible Neuroprotective Strategies in ALS
Current Neuropharmacology Editorial: Glia-Neuron Crosstalk and its Therapeutic Implication in Neuropsychiatric Disorders
Current Neuropharmacology Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease
Current Medicinal Chemistry Therapeutic Agents for COVID-19: an Overview
Current Drug Therapy Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes
Current Pharmaceutical Design Pharmacological Treatment of Cannabis-Related Disorders: A Narrative Review
Current Pharmaceutical Design Transconjunctival Sutureless 23-gauge Vitrectomy for Diabetic Retinopathy. Review
Current Diabetes Reviews Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies
Current Neuropharmacology Cognitive Behavioral Therapy Online for Adult Depression: A 10 Year Systematic Literature Review
Current Psychiatry Research and Reviews Drug Choices and Advancements for Managing Depression in Parkinson's Disease
Current Neuropharmacology Potential Application of Centrifuges to Protect the CNS in Space and on Earth
Current Alzheimer Research Crocin Protects Against Beta-Amyloid Peptide-Induced Apoptosis in PC12 Cells Via the PI3 K Pathway
Current Molecular Pharmacology New Synthesis of Tic-Hydantoins Sigma-1 Ligands and Pharmacological Evaluation on Cocaine-Induced Stimulant Effects
Medicinal Chemistry Structure-Based Discovery of PDEs Inhibitors
Current Topics in Medicinal Chemistry The Neurobiological Bases for the Pharmacotherapy of Nicotine Addiction
Current Pharmaceutical Design